ALX Oncology Holdings Inc. (ALXO)

Market Cap	267.77M +935.9%
Revenue (ttm)	n/a
Net Income	-88.87M
EPS	-1.34
Shares Out	134.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	531,153
Open	1.990
Previous Close	1.990
Day's Range	1.970 - 2.015
52-Week Range	0.404 - 2.660
Beta	0.41
Analysts	Strong Buy
Price Target	4.60 (+131.16%)
Earnings Date	May 8, 2026

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 17, 2020
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: ALXO
• Website: https://www.alxoncology.com

Analyst Summary

According to 7 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 131.16% from the latest price.

Price Target

$4.6

(131.16% upside)

Analyst Consensus: Strong Buy